IOVANCE BIOTHERAPEUTICS INC's ticker is IOVA and the CUSIP is 462260100. A total of 174 filers reported holding IOVANCE BIOTHERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.11 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $28,146 | -99.2% | 6,186 | -98.7% | 0.00% | – |
| Q2 2023 | $3,341,804 | -35.5% | 474,688 | -44.0% | 0.00% | – |
| Q1 2023 | $5,182,392 | +14835.7% | 848,182 | +15520.3% | 0.00% | – |
| Q4 2022 | $34,698 | -94.3% | 5,430 | -91.4% | 0.00% | – |
| Q3 2022 | $605,000 | -46.4% | 63,144 | -38.2% | 0.00% | – |
| Q2 2022 | $1,128,000 | -95.2% | 102,147 | -92.7% | 0.00% | -100.0% |
| Q1 2022 | $23,270,000 | -39.8% | 1,397,642 | -31.0% | 0.00% | -33.3% |
| Q4 2021 | $38,679,000 | -19.6% | 2,026,166 | +3.9% | 0.00% | -25.0% |
| Q3 2021 | $48,102,000 | -31.0% | 1,950,618 | -27.2% | 0.00% | -20.0% |
| Q2 2021 | $69,686,000 | +126.1% | 2,678,159 | +175.1% | 0.01% | +66.7% |
| Q1 2021 | $30,817,000 | -70.8% | 973,375 | -57.2% | 0.00% | -66.7% |
| Q4 2020 | $105,449,000 | +6.3% | 2,272,603 | -24.6% | 0.01% | -10.0% |
| Q3 2020 | $99,189,000 | +10.6% | 3,013,023 | -7.8% | 0.01% | 0.0% |
| Q2 2020 | $89,666,000 | -10.5% | 3,266,561 | -2.4% | 0.01% | -28.6% |
| Q1 2020 | $100,186,000 | +24.2% | 3,346,801 | +14.8% | 0.01% | +55.6% |
| Q4 2019 | $80,687,000 | +47.5% | 2,914,971 | -3.0% | 0.01% | +28.6% |
| Q3 2019 | $54,715,000 | -18.7% | 3,006,357 | +9.5% | 0.01% | -12.5% |
| Q2 2019 | $67,319,000 | +617.8% | 2,745,486 | +178.4% | 0.01% | +700.0% |
| Q1 2019 | $9,379,000 | -7.2% | 986,200 | -13.7% | 0.00% | 0.0% |
| Q4 2018 | $10,108,000 | -41.0% | 1,142,200 | -25.1% | 0.00% | -50.0% |
| Q3 2018 | $17,146,000 | -29.3% | 1,524,100 | -19.5% | 0.00% | -33.3% |
| Q2 2018 | $24,240,000 | -24.3% | 1,893,746 | 0.0% | 0.00% | -25.0% |
| Q1 2018 | $32,004,000 | +122.5% | 1,893,746 | +5.3% | 0.00% | +100.0% |
| Q4 2017 | $14,384,000 | +3.2% | 1,798,028 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $13,935,000 | -33.1% | 1,798,028 | -36.6% | 0.00% | -33.3% |
| Q2 2017 | $20,833,000 | – | 2,834,373 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Perceptive Advisors | 12,201,261 | $203,150,000 | 4.07% |
| Paradigm Biocapital Advisors LP | 907,428 | $15,109,000 | 4.00% |
| Avoro Capital Advisors LLC | 9,125,000 | $151,931,000 | 2.77% |
| Logos Global Management LP | 1,000,000 | $16,650,000 | 2.16% |
| Avidity Partners Management LP | 6,043,219 | $100,620,000 | 2.10% |
| Orbimed Advisors | 6,633,006 | $110,440,000 | 1.79% |
| Parametrica Management Ltd | 134,679 | $2,240,000 | 1.66% |
| Boxer Capital, LLC | 1,935,133 | $32,220,000 | 1.66% |
| Fairmount Funds Management LLC | 389,588 | $6,487,000 | 1.53% |
| Long Focus Capital Management, LLC | 705,000 | $11,738,000 | 1.51% |